
Historically, the biggest barrier to enrolling diverse populations in clinical trials has been a lack of establishing trusting relationships between researchers and communities and their residents, explained C. Daniel Mullins, PhD, professor in the Pharmaceutical Health Services Research Department at the University of Maryland School of Pharmacy.

